BiotechTube
Immorta Bio

Immorta Bio

San Diego, United States· Est.
immortabio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Immorta Bio is an early-stage, private biotech focused on pioneering therapies to reverse aging. The company is advancing two core technology platforms: SenoVax™, an autologous approach to eliminate senescent cells, and StemCell Revivify™, designed to rebuild damaged organs and tissues with stem cells. While still in pre-clinical development, the company has reported promising mouse model data showing lifespan extension. It is led by a team of seasoned biotech entrepreneurs and pharmaceutical industry veterans.

AgingLongevityAge-related Diseases

Technology Platform

Dual-platform approach: 1) SenoVax™ - Autologous cell therapy platform targeting senescent cells (senolytics). 2) StemCell Revivify™ - Stem cell-based platform for tissue and organ regeneration.

Opportunities

The company operates in the high-growth, paradigm-shifting longevity therapeutics space, targeting the root cause of multiple chronic diseases.
Successful translation of its platform technologies could create a new category of preventative and regenerative medicine with a vast addressable market.
Early promising pre-clinical data in animal models provides a foundation for attracting investment and strategic partnerships.

Risk Factors

Extreme scientific and translational risk in moving from mouse lifespan studies to human anti-aging therapies.
Unclear regulatory pathway for aging as an indication and high clinical trial risk for initial age-related disease targets.
Heavy reliance on future capital raises in a competitive funding environment for pre-clinical biotechs.

Competitive Landscape

Immorta Bio competes in the rapidly evolving longevity biotech sector with companies like Unity Biotechnology (senolytics), Altos Labs (cellular reprogramming), and Life Biosciences, among others. Its specific autologous cell therapy approach to senolysis may differentiate it from small-molecule senolytic competitors. The field is characterized by high ambition, significant private investment, and collaboration with academic pioneers.

More companies in Cell & Gene Therapy →More companies in United States →